Equillium, Inc. (EQ)
| Market Cap | 21.86M |
| Revenue (ttm) | 24.64M |
| Net Income (ttm) | -28.95M |
| Shares Out | 34.41M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,958 |
| Open | 0.630 |
| Previous Close | 0.630 |
| Day's Range | 0.630 - 0.650 |
| 52-Week Range | 0.480 - 3.200 |
| Beta | 1.20 |
| Analysts | Strong Buy |
| Price Target | 6.50 (+923.46%) |
| Earnings Date | May 11, 2023 |
About EQ
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment o... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for EQ stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 923.46% from the latest price.
News
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #celiacdisease--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therape...
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to ...
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammato...
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders...
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement.
Equillium's Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders...
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders...
SHAREHOLDER ALERT: Weiss Law Investigates Equillium, Inc.
NEW YORK,, Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Equillium, Inc. ("Equillium" or the "Co...
SHAREHOLDER ALERT: Weiss Law Investigates Metacrine, Inc.
NEW YORK , Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Metacrine, Inc. ("Metacrine" or the "Co...
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders...
Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders...
Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata
LA JOLLA, Calif.
Equillium to Present at Two Upcoming Investor Conferences
LA JOLLA, Calif.
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
LA JOLLA, Calif.
Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease
LA JOLLA, Calif.
Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference
LA JOLLA, Calif.
METACRINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Metacrine Inc. - MTCR
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Metacrine Inc....
Equillium's stock is up 12% after sharing early data about its investigational lupus treatment
Shares of Equillium Inc. EQ, -3.98% gained 12.9% in premarket trading on Tuesday after the company shared a batch of interim data from an early stage trial evaluating its experimental treatment in 13 ...
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders w...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT
NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache...